257 related articles for article (PubMed ID: 12697888)
21. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
Masoudi FA; Havranek EP; Wolfe P; Gross CP; Rathore SS; Steiner JF; Ordin DL; Krumholz HM
Am Heart J; 2003 Aug; 146(2):250-7. PubMed ID: 12891192
[TBL] [Abstract][Full Text] [Related]
22. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
[TBL] [Abstract][Full Text] [Related]
24. The effects of managed care and competition on community-based clinical research.
Carpenter WR; Weiner BJ; Kaluzny AD; Domino ME; Lee SY
Med Care; 2006 Jul; 44(7):671-9. PubMed ID: 16799362
[TBL] [Abstract][Full Text] [Related]
25. Analysis of treatment practices for elderly cancer patients in Ontario, Canada.
Townsley C; Pond GR; Peloza B; Kok J; Naidoo K; Dale D; Herbert C; Holowaty E; Straus S; Siu LL
J Clin Oncol; 2005 Jun; 23(16):3802-10. PubMed ID: 15923574
[TBL] [Abstract][Full Text] [Related]
26. Impact of managed care on cancer trial enrollment.
Gross CP; Krumholz HM
J Clin Oncol; 2005 Jun; 23(16):3811-8. PubMed ID: 15923575
[TBL] [Abstract][Full Text] [Related]
27. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
Evans WK; Coyle D; Gafni A; Walker H;
Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
[TBL] [Abstract][Full Text] [Related]
28. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.
Jatoi A; Hillman S; Stella P; Green E; Adjei A; Nair S; Perez E; Amin B; Schild SE; Castillo R; Jett JR;
J Clin Oncol; 2005 Dec; 23(36):9113-9. PubMed ID: 16361618
[TBL] [Abstract][Full Text] [Related]
29. Cancer treatment protocols. Who gets chosen?
Goodwin JS; Hunt WC; Humble CG; Key CR; Samet JM
Arch Intern Med; 1988 Oct; 148(10):2258-60. PubMed ID: 3178383
[TBL] [Abstract][Full Text] [Related]
30. Different rates of clinical trial enrollment between adolescents and young adults aged 15 to 22 years old and children under 15 years old with cancer at a children's hospital.
Shaw PH; Ritchey AK
J Pediatr Hematol Oncol; 2007 Dec; 29(12):811-4. PubMed ID: 18090927
[TBL] [Abstract][Full Text] [Related]
31. The evolution of the State Children's Health Insurance Program (SCHIP) in New York: changing program features and enrollee characteristics.
Dick AW; Klein JD; Shone LP; Zwanziger J; Yu H; Szilagyi PG
Pediatrics; 2003 Dec; 112(6 Pt 2):e542. PubMed ID: 14654676
[TBL] [Abstract][Full Text] [Related]
32. Clinical trial recruitment challenges with older adults with cancer.
Payne JK; Hendrix CC
Appl Nurs Res; 2010 Nov; 23(4):233-7. PubMed ID: 21035034
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of women with gynecologic cancer who enter clinical trials.
Luck MB; McIntire M; Blades N; Robinson W
J Reprod Med; 2005 Jul; 50(7):481-5. PubMed ID: 16130843
[TBL] [Abstract][Full Text] [Related]
34. Predictors of enrollment in lung cancer clinical trials.
Du W; Gadgeel SM; Simon MS
Cancer; 2006 Jan; 106(2):420-5. PubMed ID: 16342295
[TBL] [Abstract][Full Text] [Related]
35. Willingness of gynecologic cancer patients to participate in clinical trials.
Mathews C; Restivo A; Raker C; Weitzen S; Disilvestro P
Gynecol Oncol; 2009 Jan; 112(1):161-5. PubMed ID: 18952272
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care.
Meyers FJ; Linder J; Beckett L; Christensen S; Blais J; Gandara DR
J Pain Symptom Manage; 2004 Dec; 28(6):548-56. PubMed ID: 15589080
[TBL] [Abstract][Full Text] [Related]
37. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.
Moore DH; Kauderer JT; Bell J; Curtin JP; Van Le L
Gynecol Oncol; 2004 Aug; 94(2):368-74. PubMed ID: 15297174
[TBL] [Abstract][Full Text] [Related]
38. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group.
Brundage M; Osoba D; Bezjak A; Tu D; Palmer M; Pater J;
J Clin Oncol; 2007 Nov; 25(32):5078-81. PubMed ID: 17991924
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.
Sorbye H; Pfeiffer P; Cavalli-Björkman N; Qvortrup C; Holsen MH; Wentzel-Larsen T; Glimelius B
Cancer; 2009 Oct; 115(20):4679-87. PubMed ID: 19562777
[TBL] [Abstract][Full Text] [Related]
40. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
